The impact of COVID-19 on antimicrobial prescription and drug resistance in fungi and bacteria

• Published in: Brazilian journal of microbiology Vol. 53; no. 4; pp. 1925 - 1935
• Main Authors: Singulani, Junya L., Silva, Danielle L., Lima, Caroline M., Magalhães, Vanessa C. R., Baltazar, Ludmila M., Peres, Nalu T. A., Caligiorne, Rachel B., Moura, Alexandre S., Santos, Ana Raquel O., Fereguetti, Tatiani, Martins, Juliana C., Rabelo, Lívia F., Lyon, Ana C., Johann, Susana, Falcão, Juliana P., Santos, Daniel A.
• Format: Journal Article
• Language: English
• Published: Cham Springer International Publishing 01.12.2022; Springer Nature B.V
• Subjects: Antibacterial agents; Antibiotics; Antiinfectives and antibacterials; Antimicrobial agents; Azithromycin; Bacteria; Biomedical and Life Sciences; Ceftriaxone; Cephalosporins; Clinical Microbiology - Research Paper; Complications; Coronaviruses; COVID-19; Drug resistance; Fluconazole; Food Microbiology; Fungi; Gram-positive bacteria; Hospitalization; Infections; Life Sciences; Medical Microbiology; Meropenem; Micafungin; Microbial Ecology; Microbial Genetics and Genomics; Microbiology; Microorganisms; Multidrug resistance; Mycology; Oxacillin; Phenotypes; Polymyxin B; Strains (organisms); Vancomycin; COVID-19; Secondary infections; Antimicrobial prescription; Antimicrobial resistance
• ISSN: 1517-8382; 1678-4405
• DOI: 10.1007/s42770-022-00818-x

Secondary infections are one of the complications in COVID-19 patients. We aimed to analyze the antimicrobial prescriptions and their influence on drug resistance in fungi and bacteria isolated from severely ill COVID-19 patients. Seventy-nine severely ill COVID-19 hospitalized patients with secondary bacterial or fungal infections were included. We analyzed the prescribed antimicrobial regimen for these patients and the resistance profiles of bacterial and fungal isolates. In addition, the association between drug resistance and patients’ outcome was analyzed using correlation tests. The most prescribed antibacterial were ceftriaxone (90.7% of patients), vancomycin (86.0%), polymyxin B (74.4%), azithromycin (69.8%), and meropenem (67.4%). Micafungin and fluconazole were used by 22.2 and 11.1% of patients, respectively. Multidrug-resistant (MDR) infections were a common complication in severely ill COVID-19 patients in our cohort since resistant bacteria strains were isolated from 76.7% of the patients. Oxacillin resistance was observed in most Gram-positive bacteria, whereas carbapenem and cephalosporin resistance was detected in most Gram-negative strains. Azole resistance was identified among C. glabrata and C. tropicalis isolates. Patients who used more antimicrobials stayed hospitalized longer than the others. The patient’s age and the number of antibacterial agents used were associated with the resistance phenotype. The susceptibility profile of isolates obtained from severely ill COVID-19 patients highlighted the importance of taking microbial resistance into account when managing these patients. The continuous surveillance of resistant/MDR infection and the rational use of antimicrobials are of utmost importance, especially for long-term hospitalized patients with COVID-19.